Vycor Medical, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.6M | $1.5M | $1.2M | $1.4M | $1.1M | $1.4M | $1.5M |
| Cost of Revenue | $302.3K | $166.8K | $145.0K | $140.6K | $134.7K | $132.5K | $134.8K | $169.6K |
| Gross Profit | $1.6M | $1.4M | $1.3M | $1.1M | $1.3M | $1.0M | $1.3M | $1.3M |
| Gross Margin | 83.8% | 89.5% | 90.1% | 88.5% | 90.3% | 88.4% | 90.3% | 88.8% |
| Operating Expenses | ||||||||
| Research & Development | $10.0K | $15.3K | $22.6K | — | $15.2K | $0 | $0 | — |
| SG&A Expense | $1.5M | $1.4M | $1.2M | $1.3M | $1.6M | $1.7M | $1.8M | $2.2M |
| Operating Income | $33.9K | $-9.1K | $40.2K | $-306.5K | $-436.0K | $-727.4K | $-601.4K | $-1.3M |
| Operating Margin | 1.8% | -0.6% | 2.8% | -25.1% | -31.3% | -63.7% | -43.2% | -87.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-70.2K | $-107.0K | $-63.1K | $-399.7K | $-408.2K | $-800.3K | $-670.2K | $1.4M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-72.4K | $-107.2K | $-69.7K | $-404.9K | $-435.7K | $-822.5K | $-796.2K | $-1.4M |
| Net Margin | -3.9% | -6.7% | -4.8% | -33.1% | -31.3% | -72.0% | -57.2% | -91.4% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.05 | $-0.08 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.05 | $-0.08 |
| Shares Outstanding (Basic) | 33.4M | 32.9M | 32.6M | 31.7M | 29.6M | 27.4M | 25.3M | 23.1M |
| Shares Outstanding (Diluted) | 33.4M | 32.9M | 32.6M | 31.7M | 29.6M | 27.4M | 25.3M | 23.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |